Pharmacogenetic Influence of LOC387715/HTRA1 on the Efficacy of Bevacizumab Treatment for Age-Related Macular Degeneration in a Korean Population.
10.3341/kjo.2012.26.6.414
- Author:
Haeng Ku KANG
1
;
Myung Hun YOON
;
Dae Hyun LEE
;
Hee Seung CHIN
Author Information
1. Department of Ophthalmology and Inha Vision Science Laboratory, Inha University School of Medicine, Incheon, Korea. hschin@inha.ac.kr
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Bevacizumab;
Complement factor H Y402H;
HTRA1;
LOC387715;
Macular degeneration
- MeSH:
Aged;
Alleles;
Angiogenesis Inhibitors/administration & dosage/therapeutic use;
Antibodies, Monoclonal, Humanized/*administration & dosage/therapeutic use;
DNA/*genetics;
Female;
Follow-Up Studies;
Genotype;
Humans;
Intravitreal Injections;
Macular Degeneration/drug therapy/epidemiology/*genetics;
Male;
Pharmacogenetics/*methods;
*Polymorphism, Genetic;
Retrospective Studies;
Serine Endopeptidases/*genetics/metabolism;
Vascular Endothelial Growth Factor A/antagonists & inhibitors;
Visual Acuity
- From:Korean Journal of Ophthalmology
2012;26(6):414-422
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of this study was to determine the pharmacogenetic effects of complement factor H (CFH) Y402H, LOC387715 and high-temperature requirement factor A1 (HTRA1) genotypes on the treatment of exudative age-related macular degeneration (AMD) by intravitreal bevacizumab injection in a Korean population. METHODS: Seventy-five patients diagnosed with exudative AMD were treated with intravitreal bevacizumab (2.5 mg) monotherapy. All patients received three initial intravitreal bevacizumab injections every four weeks and were then treated "as needed" based on clinical findings, optical coherence tomography and fluorescein angiography during the 12 month follow-up period after the third injection. RESULTS: The difference in visual acuity improvement among the three genotypes of LOC387715 were statistically significant at six months post-treatment (logarithm of the minimum angle of resolution; TT, 0.346; GT, 0.264; GG, 0.188; p = 0.037). Among the LOC387715 genotypes, the number of additional injections was lower in patients who had the risk T allele (GG, 2.143; GT, 2.000; TT, 1.575; p = 0.064). There was no significant difference between visual acuity and central macular thickness change in the CFH Y402H polymorphism group during the 12 month follow-up period. However, the TC group of CFH Y402H required more additional bevacizumab injections than the TT group (TT, 1.517; TC, 3.363; p = 0.020). CONCLUSIONS: This study demonstrated that different LOC387715/HTRA1 genotypes resulted in different bevacizumab treatment responses on exudative AMD. Patients with the risk allele had an improved treatment response and less need for additional injections. However, patients with the CFH Y402H risk allele needed more additional injections of bevacizumab in order to improve visual acuity. This study illustrates how pharmacogenetic factors may help determine treatment modality and dosing. This could ultimately provide basic data for 'personalized medicine' in AMD.
